Australia Opens The Door for SKY-0515: Skyhawk Seeks Provisional Approval for Its Oral HD Drug

Skyhawk Therapeutics announced on March 3, 2026 that Australia’s Therapeutic Goods Administration (TGA) has determined that SKY-0515, an small molecule drug that can be taken as a pill to lower huntingtin levels, meets eligibility criteria for registration via the provisional approval pathway for Huntington’s disease (HD). Skyhawk has submitted its formal provisional approval application to the TGA, initiating a review that could allow earlier access to SKY-0515 based on preliminary clinical data, prior to completion of full Phase 3 trials. This regulatory milestone represents an important step toward potential approval in Australia, though provisional determination does not guarantee approval or access to this drug for HD families.

A Refresher: What Is SKY-0515?

HD is caused by an expansion in the DNA letter code of the huntingtin (HTT) gene. One of the most explored strategies for treating it is lowering the levels of the harmful huntingtin protein that the expanded gene produces. Many companies are working on drugs that do exactly this, but they differ substantially in how they do it, ranging from brain surgery, to spinal injections, to a daily pill. 

SKY-0515, developed by Skyhawk Therapeutics, is an oral drug taken as a once-daily pill that works by targeting the genetic messages (called RNA) that cells use as instructions for making proteins. By tweaking how those messages are processed, SKY-0515 reduces how much huntingtin the body produces. 

Drugs that work this way are called splice modulators, and a previous generation of them helped pave the way for SKY-0515. What sets SKY-0515 apart is its potency: in early trials, a low 9 mg dose lowered huntingtin levels by around 70%. That level of lowering in a once-daily pill is something the field hadn’t achieved before.

Skyhawk also believes SKY-0515 has a second trick up its sleeve. The drug appears to also lower a protein called PMS1, which plays a role in “somatic expansion”, the process by which the genetic expansion in the HTT gene gets progressively longer in certain cells over time, particularly in the brain of people with HD. If SKY-0515 can slow that process, it could address two different drivers of HD at once. 

However, we should be clear: while Skyhawk has reported that PMS1 is lowered by SKY-0515, we don’t yet have enough data to know whether those reductions are large enough to meaningfully slow somatic expansion. That’s an important open question we’ll be watching for in future updates.

Skyhawk’s CEO Bill Haney described the TGA’s determination as “an important first step toward what could be an accelerated path to approval in Australia and the world.”

Why Is This Trial Happening in Australia?

HDBuzz readers may have noticed that SKY-0515’s Phase 1 trial has been running in Australia, and that the ongoing Phase 2/3 FALCON-HD trial is also focused there (along with New Zealand). That’s not just happenstance.

Australia has become a popular location for early-phase clinical trials for several reasons. Clinical trial costs in Australia are lower than in the United States, where the expense of running trials is substantial. 

And while regulatory requirements for safety and ethics are rigorous, Australia has less bureaucratic red tape than some other countries, allowing trials to move faster through the early phases. For companies trying to gather safety and efficacy data quickly, Australia offers a practical and efficient environment.

Enter the TGA, Australia’s Drug Regulator

The body responsible for approving medicines in Australia is the Therapeutic Goods Administration, or TGA. Think of the TGA as Australia’s equivalent of the FDA in the United States or the EMA in Europe. It reviews evidence on a drug’s safety, quality, and effectiveness before deciding whether it can be prescribed.

Like those other agencies, the TGA has created special faster pathways for medicines that treat serious or life-threatening diseases where there is a real unmet need. One of these is the provisional approval pathway, which is designed to get promising medicines to people with these diseases sooner than a standard review timeline, without waiting for every last piece of clinical evidence to come in.

What Does “Provisional Approval” Actually Mean?

Here’s how it works. Normally, a drug company needs to complete large Phase 3 clinical trials before a regulator will grant full approval. That process can take many years. The provisional pathway allows a company to apply for approval based on earlier, preliminary data, as long as the drug is for a serious condition with limited treatment options and shows promising early signs of working.

Provisional registration is time-limited: it’s granted initially up to two years, with the option to extend up to a maximum of six years. This gives the company time to generate the comprehensive data needed for full approval. It’s essentially a conditional yes: the drug can be made available to people now, while the company keeps gathering the evidence ultimately needed for the usual approval procedure. 

The major caveat here is that if that additional evidence suggests the drug doesn’t actually do what the company wants it to do, which is reducing progression of HD in this case, its approval will be rescinded and the drug will be pulled from the market. This pathway isn’t a guarantee for permanent availability, but rather a mechanism to get promising drugs to as many people in need as fast as possible.

The TGA’s recent announcement is that SKY-0515 has been found eligible for this pathway. This means the regulator has reviewed Skyhawk’s application and agreed the drug meets the criteria to be considered. Skyhawk submitted its formal application for provisional approval to the TGA on March 3, 2026. That submission now kicks off the full TGA review process, which will determine whether SKY-0515 actually receives provisional registration and can be prescribed in Australia.

To be clear: this is not approval. Eligibility is the door opening, the review is the walk through it.

This pathway isn’t a guarantee for permanent availability, but rather a mechanism to get promising drugs to as many people in need as fast as possible.

What Does This Mean for People with HD?

More than 115 participants have now been given SKY-0515 in the clinical setting. The ongoing FALCON-HD Phase 2/3 trial is testing whether SKY-0515 can slow the progression of HD symptoms, testing movement, thinking, and daily function, in over 500 people with Stage 2 or early Stage 3 HD. While over 40 sites across the globe will eventually open in this trial, currently only 11 in Australia and New Zealand are open and enrolling. 

Given recent regulatory setbacks in the U.S. based on clinical trial design, it’s worth noting that FALCON-HD is designed as a double blind, placebo-controlled study, where some participants will be given a sugar pill rather than comparing those given SKY-0515 to natural history studies.

If Skyhawk’s provisional approval application succeeds, it would mean that people with HD in Australia could potentially access SKY-0515 before the full Phase 3 results are in, an important consideration for a community where time is not a luxury everyone has. It would also put SKY-0515 on a regulatory path that could open doors to approval processes in other countries.

Skyhawk’s CEO Bill Haney described the TGA’s determination as “an important first step toward what could be an accelerated path to approval in Australia and the world.”

That optimism is understandable. But the HD community has also learned, through hard lived experience, to hold regulatory milestones carefully. Eligibility for a regulatory pathway is not the same as approval, and approval is not the same as a treatment in hand. We’ll be watching the TGA’s review process and the FALCON-HD trial results closely, and we’ll keep you updated.

Summary

• Australia’s drug regulator, the TGA, has determined that SKY-0515, an oral huntingtin-lowering drug, is eligible to apply for provisional (accelerated) approval
• Skyhawk submitted its formal provisional approval application to the TGA on March 3, 2026
• Provisional approval could allow SKY-0515 to reach people with HD in Australia sooner than a standard review process, based on early clinical data
• SKY-0515 is an oral splice modulator, which is a pill that works by changing how cells process genetic messages, and has shown strong huntingtin-lowering in early trials
• More than 115 participants are now enrolled in trials of SKY-0515
• This is a regulatory milestone, not an approval; the TGA still needs to complete its full review before SKY-0515 can be prescribed to anyone